Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Clinical trial NCT06590558 · WITHDRAWN

Trial details

NCT number: NCT06590558
Sponsor: National Cancer Institute (NCI)
Status: WITHDRAWN
Phase: Phase 1
Study type: INTERVENTIONAL

Anatomic Stage III Breast Cancer AJCC v8 Anatomic Stage IV Breast Cancer AJCC v8 Invasive Breast Carcinoma Locally Advanced HER2-Negative Breast Carcinoma Locally Advanced Hormone Receptor-Positive Breast Carcinoma Locally Advanced Triple-Negative Breast Carcinoma Metastatic HER2-Negative Breast Carcinoma Metastatic Hormone Receptor-Positive Breast Carcinoma Metastatic Triple-Negative Breast Carcinoma Unresectable HER2-Negative Breast Carcinoma Unresectable Hormone Receptor-Positive Breast Carcinoma Unresectable Triple-Negative Breast Carcinoma

Start date: 2025-08-04
Primary completion: 2027-05-17
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.